甘李药业 (603087.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

26.1x

EV/EBITDA

26.7x

Market Cap

CNY 39.11B

MomentumView details →

1D Return

−4.33%

YTD Return

+2.98%

RSI (14)

50.8

ValuationView details →

P/E (Fwd)

26.1x

EV/EBITDA

26.7x

Market Cap

CNY 39.11B

RSI (14)

50.8

MomentumView details →

1D Return

−4.33%

YTD Return

+2.98%

ProfitabilityView details →

Gross Margin

75.33%

Net Margin

25.96%

EBITDA Margin

37.70%

ROE (TTM)

8.66%

ROA (TTM)

8.08%

Asset Turnover

0.31x

GrowthView details →

Revenue YoY

+13.70%

EPS YoY

+23.23%

FCF YoY

—

Revenue CAGR 3Y

+33.26%

EPS CAGR 3Y

+79.35%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.68

EPS Surprise

−10.37%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.60

Avg Surprise (4Q)

−10.37%

Rev Surprise

1.71%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

7.99x

Quick Ratio

6.37x

Div Yield

1.43%

Div Rate

CNY 1.00

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

3.95B

Net Income (TTM)

1.02B

Op. CF (TTM)

797.20M

Next earningsOct 22, 2026 →

Latest newsMore news →

Ganli Pharmaceutical announced its 2026 first-half results: revenue of 2.223 billion yuan, up 7.56% year-on-year; net profit attributable to shareholders of 610 million yuan, up 1.01% year-on-year.10d ago

Ganlee Pharmaceutical's subsidiary Ganlee Shandong received approval from China's National Medical Products Administration to conduct clinical trials for GZC8072 tablets for weight control.11d ago

Similar companies

Alcon Inc.ALC ResMed Inc.RMD Medline Inc.MDLN 奕瑞科技688301.SH Becton, Dickinson and CompanyBDX West Pharmaceutical Services, Inc.WST Find similar companies →

Latest newsMore news →

Ganli Pharmaceutical announced its 2026 first-half results: revenue of 2.223 billion yuan, up 7.56% year-on-year; net profit attributable to shareholders of 610 million yuan, up 1.01% year-on-year.10d ago Ganlee Pharmaceutical's subsidiary Ganlee Shandong received approval from China's National Medical Products Administration to conduct clinical trials for GZC8072 tablets for weight control.11d ago